DataRoom AM: Leighton's China boost

The construction giant's planned sale of John Holland gets a booster shot from the China free-trade agreement, while mum and dad investors flock to the Medibank stock offering.

The Chinese free-trade deal is drawing mixed reviews from the gamut of impacted parties, but one company that may have cause for celebration is Leighton Holdings as it looks to accelerate its asset sales plan.

Elsewhere, Medibank Private races toward a very successful ASX debut, Alinta Energy faces a valuation quandary, Anchorage eyes off a Pacific Brands division and Estia Health receives some good news ahead of its IPO.



{{ twilioFailed ? 'SMS Code Failed to Send…' : 'An SMS verification code has been sent ...' }}

Hi {{ user.FirstName }}

Looks like you have already taken a free trial

Please enter your payment details

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to complete your SMS verification

We cannot send you a code via SMS to {{user.DayPhone}}

If you didn't receive SMS code please

SMS code cannot be sent due to: {{ twilioStatus }}

Please select one of the options below:

Looks you are already a member. Please enter your password to proceed

Please untick this box when using a public or shared device

Verify your mobile number to proceed...

Please check your mobile number below and press the Send Verification Code button. This will be used to complete your verification in the next step.

Please sign up for full access


Updating information

Please wait ...


{{ productPrice }} / day
( GST included )
Price $0
GST $0
Discount -{{productDiscount}}
TOTAL {{productPrice}}
  • Mastercard
  • Visa

Please click on the ACTIVATE button to finalise your membership


The email address you entered is registered with InvestSMART.

Please login or select "Don't know password"

Please untick this box when using a public or shared device

Register as a new member

(using a different email)

Related Articles